At a cost of $199, 23andMe’s DNA test is considerably less expensive than testing in a medical office, which can run into thousands of dollars. Existing customers of 23andMe are expected to have access to the test within the next few weeks.
BRCA gene mutations have been linked to a higher risk of developing breast cancer. While there are more than one thousand known mutations, the DNA test from 23andMe screens for three specific mutations that are found primarily in people of Ashkenazi Jewish descent.
It’s estimated that one in 40 Ashkenazi Jews has one of the mutations, which results in a 45 to 85 percent chance of women developing breast cancer by the age of 70 as well as a higher risk of ovarian cancer. Men can also carry one of the mutations along with a risk of breast cancer.
How Effective Is Consumer Genetic Testing?
Geneticist Eric Topol of the Scripps Institute cautions that 23andMe’s test is a start, but testing needs to be more comprehensive. Topol adds that, since the test is limited to three mutations, people may get a false sense of security when they are actually carrying other mutations outside the scope of the test.
Here at Issels®, we treat many types of cancer with immunotherapy, including thyroid cancer. Thyroid cancer diagnoses have risen over the last 30 years and it is now the 8th most common cancer in the United States.
Role of the Thyroid
The thyroid gland is found in the front of the throat area and is very important. Its multiple tasks include producing several hormones, which work to control the heart rate and regulate body temperature. The thyroid also aids in controlling the amount of calcium in the bloodstream and regulating metabolism.
Cancer of the thyroid is most commonly found in middle-aged white females, but it also occurs in both men and women of all ages. It is a slow-growing cancer and is markedly treatable. People with exposure to radiation also have an increased risk of developing thyroid cancer.
A hoarse voice, neck pain and lymph nodes that are enlarged are some of the early signs of thyroid cancer. Thyroid nodules are not common in children or teens but become more prevalent as people get older.
While the papillary and mixed papillary/follicular thyroid cancer is the most prevalent type, there are three other types, including follicular/Hurtle cell, medullary and anaplastic. The most common types are the most curable, with a cure rate of over 97%.
At Issels®, we can help you find the right combination of thyroid cancer immunotherapy treatment that will help you flourish. Contact us to learn more about our immunotherapy cancer treatment breakthrough.
It’s important to understand the difference between common moles that often occur on the skin and melanomas. To the untrained eye, the two can look very similar, and they can result in people either worrying unnecessarily about the condition of their skin or overlooking skin irregularities that require immediate medical attention.
At Issels®, we’ve worked with many people who have been diagnosed with melanoma, and immunotherapy has been shown to be a very promising alternative to traditional cancer treatments. Even so, identification remains a serious challenge, and the National Cancer Institute has come up with a tool to help.
The Moles to Melanoma Tool
The Moles to Melanoma tool from the National Cancer Institute provides individuals with pictures that help to understand the three types of moles that can appear on the human body. They are:
Dysplastic Nevi (or DN)
Common moles are those that are non-cancerous, and their characteristics are not a cause for concern. Dysplastic Nevi moles are those that aren’t cancerous, but that possess qualities that would cause doctors to keep an eye on them for any changes that could indicate melanoma. Finally, melanoma is characterized by moles that fit into the ABCDE category of identification.
Are You Concerned About Melanoma?
If your family has a history of melanoma, or if you have moles that cause you to be concerned, this tool can be very useful for you. However, it’s important to remember that no diagnostic tool should ever take the place of a professional diagnosis from an experienced physician.
We believe at Issels® Immuno-Oncology that integrative immunotherapy treatment plans are critical for successful patient outcomes; which is why we are so excited about the following prostate cancer risk detection and screening news:
The National Cancer Institute estimates that approximately 27,540 American men will die from prostate cancer this year. Yet, as reported in the New England Journal of Medicine, researchers have finally found their first link between inherited genes and prostate cancer — a HOXB13 gene mutation.
Researchers took samples from 5,100 prostate cancer patients who were 55 years old or younger (94 families represented) and 1,400 healthy men. After sequencing more than 200 genes, they found the following:
72 men in four families carried the same HOXB13 gene mutation.
Only one man in the control group had it.
Although these results aren’t definitive proof that the mutation causes prostate cancer, it does appear to be a factor. The researchers also found two more mutations among African men, but they need a larger sampling to confirm if these mutations also play a role.
The Big Picture
Doctors trace the risk of inherited breast cancer in women through tests that look for mutations of BRCA1 and BRCA2 genes that can contribute to cancer growth. The HOXB13 mutation offers hope that doctors might one day be able to test men for genetic links in a similar fashion.
Since men with the HOXB13 gene mutation carry 10-20 times more risk of getting prostate cancer before they reach 55 years old, the discovery of this gene is a scientific breakthrough. At Issels®, we search for breakthroughs like these every single day. Contact us today for more information!
At Issels®, our goal is providing each cancer patient alternative programs that include personalized treatment to address their needs. These include non-toxic therapies and our non-toxic immunobiologic core treatment for many types of the disease including prostate cancer.
In an article published by UK based, The Telegraph, the question was asked if researchers were making advances in detecting prostate cancer in its early stages as the number of men with prostate cancer was rising significantly. The article stated that from the research findings of Macmillan Cancer Support, the stats show more than 30,000 men living in the UK are in the advanced stages of incurable prostate cancer. Research also indicates that prostate cancer will lead the list as the most common cancer for men by the year 2030.
Along with the rise in diagnosed cases, more men are insisting on in-depth research. To this end, new drugs are currently in development and more research is underway to shed light on the progression and treatment of the disease. Men are also being better educated as to the importance of early detection through self-checks.
According to the CEO of Prostate Cancer UK, Owen Sharp, “A man in the UK dies each hour from prostate cancer and another is diagnosed every 15 minutes…” This is unacceptable on every level and is why more research, more testing options, better drugs, and continued awareness by men of the importance of making an appointment with their doctor, early on, is of the utmost importance.
For more information about our alternative programs regarding prostate cancer, please contact our staff via our toll free numbers for the US, Canada, and international inquiries, or use the online form both at our website.